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Observational Study
Abstract
AIM
To evaluate the outcomes in biological treatment and 
quality of life of psoriatic patients with chronic hepatitis 
C (CHC) treated with new Direct-Acting Antiviral agents 
(DAAs) compared to pegylated interferon-2α plus 
ribavirin (P/R) therapy.
METHODS
This is a retrospective study involving psoriatic patients in 
biological therapy who underwent anti-hepatitis C virus 
(HCV) treatment at the Department of Dermatology 
Galeazzi Orthopaedic Institute Milan, Italy from January 
2010 to November 2017. The patients were divided into 
two groups: patients that underwent therapy with DAAs 
and patients that underwent HCV treatment with P/R. 
Patients were assessed by a dermatologist for psoriasis 
symptoms, collecting Psoriasis Area Severity Index 
(PASI) scores and the Dermatology Quality of Life Index 
(DLQI). PASI and DLQI scores were evaluated 24 wk 
after the end of HCV treatment and were assumed as 
an outcome of the progression of psoriasis. Switching to 
a different bDMARD was considered as an inadequate 
response to biological therapy. The dropout of HCV 
therapy and sustained virological response (SVR) were 
considered as outcomes of HCV therapy.
RESULTS
Fifty-nine psoriatic patients in biological therapy 
underwent antiviral therapy for CHC. Of this, 27 patients 
were treated with DAAs and 32 with P/R. After 24 wk 
post treatment, the DLQI and the PASI scores were 
significantly lower (P < 0.001 and P < 0.005, respectively) 
in the DAAs group compared with P/R group. None of the 
patients in the DAAs group (0/27) compared to 8 patients 
of the P/R group (8/32) needed a shift in biological 
treatment.
CONCLUSION
DAAs seem to be more effective and safe than P/R in 
HCV-positive psoriatic patients on biological treatment. 
Fewer dermatological adverse events may be due to inter-
feron-free therapy.
Key words: Hepatitis C virus; New Direct-Acting Antiviral 
agents; Psoriasis; Biological disease modifying drugs
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Psoriasis is a chronic inflammatory disease 
affecting approximately the 2% of population in 
Europe and North America. The hepatitis C virus (HCV) 
infection affects approximately the 3% of the world 
population with an estimated prevalence of 5 million 
people in the United States. Up to 0.06% of people in 
the United States suffer from both psoriasis and HCV. 
Psoriatic patients with HCV are excluded by randomized 
controlled clinical trials. Therefore, no data is currently 
available concerning the concomitant administration of 
biological disease modifying drugs and the new Direct-
330 February 27, 2018|Volume 10|Issue 2|WJH|www.wjgnet.com
Damiani G et al . DAAs in HCV+ psoriatic patients
Acting Antiviral agents (DAAs) medications approved for 
the treatment of HCV infection. The aim of this study 
is to evaluate the outcomes in biological treatment and 
quality of life of psoriatic patients with HCV infection 
treated with DAAs compared to the previous standard 
therapy of Pegylated Interferon plus Ribavirin.
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C virus­positive psoriatic patients treated using pegylated 
interferon in combination with ribavirin compared to new Direct­
Acting Antiviral agents. World J Hepatol 2018; 10(2): 329­336 
Available from: URL: http://www.wjgnet.com/1948­5182/full/
v10/i2/329.htm  DOI: http://dx.doi.org/10.4254/wjh.v10.i2.329
INTRODUCTION
Psoriasis is a chronic systemic inflammatory disease 
affecting approximately 2% of the population in Europe 
and North America with approximately 7.5 million 
people in the United States[1,2]. Hepatitis C virus (HCV) 
is an infection affecting approximately 71 million people 
worldwide; the most affected regions being WHO Eastern 
Mediterranean and European Regions with a prevalence 
of 2.3% and 1.5%[3]. Prevalence of HCV infection in other 
WHO regions varies from 0.5% to 1.0%[3]. According to 
the Centers for Disease Control and Prevention, there are 
currently about 3.3 (2.7-3.9) million people with chronic 
hepatitis C (CHC) in the United States[4]. The estimated 
prevalence of both psoriasis and HCV in the United States 
is 0.02%-0.06% (55000-150000 persons)[5]. 
The pathogenesis of psoriasis remains unclear, 
however Th1/Th17 autoimmune involvement has been 
hypothesized[6]. Its association with HCV is still a matter 
of debate. Some evidence suggests that psoriasis 
may be initiated and maintained by both HCV and 
interferon-α[7]. In a large case-control study, including 
12502 psoriatic patients and 24287 controls, the 
prevalence of HCV in psoriatic patients was increased 
compared to controls (1.03% vs 0.56%; P < 0.001)[8]. 
The therapeutic armamentarium available for psoriasis 
encompasses the conventional disease modifying 
drugs (cDMARDs) and biological DMARDs (bDMARDs). 
cDMARDS represent the first line therapy in high-
need psoriatic patients, while bDMARDs are for those 
subjects in whom cDMARDs have either failed, were not 
tolerated, or were contraindicated[9]. While bDMARDs 
are generally safer than cDMARDs, there is one concern 
emerging from registries or long-term studies which 
is an increased risk of infection. When patients lose an 
adequate response to bDMARDs the possible options 
include increasing the dose, shortening the dosing 
interval, combination therapy with a topical or another 
systemic treatment, or switching to a different drug[10]. 
Recently, the standard of care for CHC has changed. 
The new Direct-Acting Antiviral agents (DAAs) such as 
Sofosbuvir, Daclatasvir and the Sofosbuvir/Ledipasvir 
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combination are now part of the preferred regimens in 
the WHO guidelines and can achieve cure rates above 
95%[3]. These agents are much more effective, safer 
and better-tolerated than older therapies involving 
pegylated interferon and ribavirin (P/R) which nowadays 
play a very limited role for specific scenarios[3]. Of the 71 
million persons living with CHC globally in 2015, 20% 
(14 million) knew their diagnosis and 7.4% of those 
diagnosed (1.1 million) were started on treatment[3]. 
Psoriatic patients with CHC are excluded by ran-
domized controlled clinical trials. Data on psoriatic 
patients with HCV infection treated with bDMARDs is 
available solely on the reports of single cases or analyses 
of small groups of patients. Therefore, no data is currently 
available concerning the concomitant administration of 
bDMARDs for psoriasis and the new DAAs approved for 
the treatment of CHC[9].
The aim of this study is to evaluate the disease 
progression and outcomes in biological treatment and 
quality of life of HCV psoriatic patients on bDMARDs also 
treated with new DAAs compared to P/R therapy.
MATERIALS AND METHODS
Study population
This is an observational analysis performed by checking 
all psoriatic patients admitted to the Department of 
Dermatology and Venereology of I.R.C.C.S. Istituto 
Ortopedico Galeazzi (Milan, Italy) after 2007. Further-
more, in the present study we collected only HCV positive 
psoriatic patients admitted in our department from 2010 
until now undergoing biological therapy. The study 
complies with the Declaration of Helsinki and all patients 
signed a standard consent regarding sensitive personal 
data treatment.
Study design
The present study is a spin-off observational retro-
spective study on HCV psoriatic patients, resulted as re-
analysis of a previous study towards the re-circulation 
of CD4+ memory T-cells in psoriatic patients, approved 
by the Institutional Review Board (Comitato Etico 
dell'Ospedale San Raffaele, Milano)[11]. This previous 
study had as exclusion criterion the absence of acute and 
chronic systemic or cutaneous infections during sample 
collections[11], conversely we enrolled the previously 
discarded HCV psoriatic patients, focusing on their HCV 
eradication management. The subjects were divided into 
two groups: (1) Patients that underwent therapy with 
DAAs (DAA-group) (2) patients that underwent HCV 
treatment with P/R (P/R-group). Patients were assessed 
by a dermatologist for psoriasis symptoms, collecting 
Psoriasis Area Severity Index (PASI) and Dermatology 
Quality of Life Index (DLQI). They were also assessed by 
a hepatologist to determine liver function while collecting 
biochemical and clinical data in two times: Baseline 
(before HCV treatment) (T0) and 24 wk after the end of 
HCV treatment (T1). The data was extracted to monitor 
psoriasis biological therapy and HCV therapy[12,13].
Inclusion criteria
Inclusion criteria were age > 18 years old, signed consent 
forms, no previous transplantation, no pregnancy, no 
hereditary hepatic diseases, no drug addiction, and no 
alcohol abusers [Alcohol Use Disorders Identification 
Test (AUDIT) score < 7], negative results at screening 
tuberculosis, absence of acute and chronic systemic or 
cutaneous infections during sample collection. Psoriasis 
diagnosis was performed by a Dermatologist following 
the Psoriasis Italian Guidelines[10], and the diagnosis of 
CHC according the WHO guidelines[14].
Exclusion criteria
Exclusion criteria were age < 18 years old, pregnancy, 
drug addiction, alcohol abusers [Alcohol Use Disorders 
Identification Test (AUDIT) score > 7], HIV infection.
Outcomes of the study
PASI, DLQI were evaluated 24 wk after the end of HCV 
treatment (T1) and were assumed as an outcome of 
the progression of psoriasis. Switching to a different 
bDMARD was considered as inadequate responses to 
biological therapy. The dropout of HCV therapy, and 
sustained virological response (SVR) were considered 
as outcomes of HCV therapy. 
Data collection and variables definitions
Baseline clinical characteristics, medical history, 
biochemical variables, and pharmacologic treatments 
employed during hospitalization were retrospectively 
collected and recorded on a computer database. SVR 
was defined as a confirmed undetectable serum HCV-
RNA level 24 wk after the discontinuation of HCV therapy. 
Patients not fulfilling the SVR definition criteria were 
classified as non-SVR. 
Statistical analysis
Continuous variables are presented as mean ± SD and 
categorical variables are presented as absolute values 
and percentages. Comparisons between continuous 
variables were performed using Mann–Whitney or 
Kruskall–Wallis tests and comparisons between categorical 
variables were performed using the χ 2 or Fisher’s exact 
test. Statistical significance was defined as P < 0.05. 
Data analysis was performed using statistical software 
R-version 3.2.4.
RESULTS
A total of 59 psoriatic patients met the inclusion criteria 
(27 in the DAA-group and 32 in the P/R-group) and 
were included in this analysis. The patients’ main 
characteristics are summarized in Table 1. All the patients 
in the P/R-group were treated with pegylated interferon-
2α plus ribavirin; in the DAA-group 25 patients (92.6%) 
were treated with Sofosbuvir plus Daclatasvir, 1 patient 
was treated with Sofosbuvir + ribavirin: 1 (3.7%) and 
1 patient (3.7%) was treated with Sofosbuvir plus 
simeprevir plus ribavirin. The median age was 56.7 ± 
Damiani G et al . DAAs in HCV+ psoriatic patients
± 0.8 in the P/R-group, respectively. The viral load at 
the baseline was 6.2 log10 ± 5.7 log10 UI/mL in the DAA-
group and 6,1 log10 ± 6.0 log10 UI/mL in the P/R-group, 
respectively. All the 27 patients (100%) in the DAA-
group obtained SVR, whereas only 37.5% (12/32) of 
patients in the P/R-group achieved a SVR. Two out of 27 
patients of DAA-group had autoimmune comorbidities: 
1 (3.7%) rheumatic arthritis and 1 (3.7%) systemic 
erythematosus lupus; 1 (3.1%) out of 32 patients of 
P/R-group had autoimmune comorbidity: ankylosing 
spondylitis. In the DAA-group other comorbidities were 
cardiovascular diseases, metabolic syndrome, chronic 
obstructive disease, and HBV in 6 (22.2%), 2 (7.4%), 5 
(18.5), 1 (3.7%) patients, respectively. In the P/R-group 
other comorbidities were cardiovascular diseases, 
metabolic syndrome, chronic obstructive disease, 
and HBV in 3 (9.4%), 1 (3.1%), 2 (6.3%), 1 (3.1%) 
patients, respectively. None of the 59 psoriatic patients 
enrolled in the study had renal insufficiency.
The comparison between the patient scores and 
laboratories findings according to HCV eradication 
treatment is shown in Table 2: There were no differences 
in PASI scores between the 2 HCV treatment groups; 
after 24 wk to the end of the HCV treatment there 
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8.9 years in the DAA-group and 58.2 ± 6.7 years in 
the P/R-group, respectively; 66.7% patients were men 
in the DAA-group and 75% patients were men in the 
P/R-group, respectively. The median body mass index 
(BMI) was 24.3 ± 2.41 in the DAA-group and 25 ± 1.86 
in the P/R-group, respectively. The median psoriasis 
duration was 21.5 ± 8.6 years in the DAA-group and 
18 ± 6.7 years in the P/R-group, respectively. In 
the DAA-group the bDMARD used, was Etanercept, 
Adalimumab, Ustekinumab and Secukinumab in 12 
(44.4%), 9 (33.3%), 5 (18.5%), and 1 (0.04%) 
patients, respectively; in the P/R-group the bDMARD 
used, was Etanercept, Adalimumab and Ustekinumab 
in 15 (46.9%), 10 (31.3%) and 7 (21.9%) patients, 
respectively. Switching among biologic therapies, before 
hepatitis C treatment, was 1.2 ± 0.3 in DAA-group 
and 1.5 ± 0.5 in P/R-group. Two patients (7.4%) of 
the DAA-group and 3 patients (9.4%) of the P/R-group 
presented psoriatic arthritis, respectively. In the DAA-
group the HCV genotypes were 1, 2 and 4 in 21 (77.8%), 
5 (33.3%) and 1 (3.7%) patients, respectively; in the 
P/R-group the HCV genotypes were 1, 2 and 3 in 29 
(90.6%), 1 (3.1%) and 2 (6.3%) patients, respectively. 
The MELD score was 9.3 ± 2.5 in DAA-group and 6.5 
Table 1  Levels of sIL-2R, ALT, and HBV DNA in the sera of patients with chronic hepatitis B virus infection (mean ± SD)
DAA-group P/R-group 
Age, yr, mean ± SD 56.7 ± 8.9 58.2 ± 6.7
Male/female, n (%) 18/9 (66.7/33.3) 24/8 (75/25)
BMI, mean ± SD, kg/m2   24.3 ± 2.41      25 ± 1.86
Psoriasis duration, yr, mean ± SD 21.5 ± 8.6    18 ± 6.7
Current biological therapy, n (%)
  Etanercept     12 (44.4)    15 (46.9)
  Adalimumab       9 (33.3)    10 (31.3)
  Infliximab - -
  Ustekinumab      5 (18.5)      7 (21.9)
  Secukinumab     1(3.7) -
Shifted biological drugs, mean ± SD   1.2 ± 0.3   1.5 ± 0.5
Psoriatic arthritis, n (%)    2 (7.4)    3 (9.4)
HCV 
Genotype, n (%)
  1    21 (77.8)    29 (90.6)
  2      5 (18.5)    1 (3.1)
  3 -    2 (6.3)
  4    1 (3.7) -
  5/6 - -
MELD score   9.3 ± 2.5   6,5 ± 0.8
HCV viral load (T0), IU/mL, mean ± SD   6.2 log10 ± 5.7 log10   6.1 log10 ± 6.0 log10
SVR, n (%) 27/27 (100) 12/32 (37.5)
Autoimmune comorbidities, n (%)
  Rheumatic arthritis    1 (3.7) -
  Ankylosing spondylitis -     1 (3.1)
  Systemic erythematosus lupus    1 (3.7) -
Other comorbidities, n (%)
  Cardiovascular disease      6 (22.2)    3 (9.4)
  Metabolic syndrome    2 (7.4)    1 (3.1)
  COPD      5 (18.5)    2 (6.3)
  Renal insufficiency 0 (0) 0 (0)
  HBV    1 (3.7)    1 (3.1)
0 (0) 0 (0)
Categorical variables are expressed as n (%). Numeric variables are expressed as median and SD. BMI: Body mass index; COPD: Chronic obstructive 
pulmonary disease; DAA: New Direct-Acting Antiviral agent; HBV: Hepatitis B virus; HCV: Hepatitis C virus; P/R: Pegylated interferon-2α plus ribavirin; 
MELD: Model for end-stage liver disease; SVR: Sustained virological response.
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was a significant reduction of PASI score in DAA-group 
when compared to P/R-group patients (P < 0.005). 
Patients in the P/R-group (8 patients, 25%) need a 
significantly (P < 0.001) frequent change of biological 
treatment compared to DAA-group (no patients). There 
was no difference in the use of topical treatments in 
the 2 groups at baseline (100% in both groups) and 
after 24 wk to the end of the HCV treatment (100% in 
both groups). Although there was no difference in the 
DLQI at the beginning of the treatment in the 2 groups, 
after 24 wk the DLQI was significantly improved in the 
DAA-group when compared to P/R-group patients (P < 
0.001). HCV treatment was significantly better tolerated 
(P < 0.005) by DAA-group patients with no dropout; 9 
out of 32 P/R-group patients (28.1%) dropped out of 
HCV treatment. HCV eradication was significantly higher 
(P < 0.005) in DAA-group compared to P/R-group: SVR 
was obtained in 100% (27/27) of patients treated with 
DAAs and in 37.5% (12/32) of patients treated with 
P/R. Three Adverse Drug Events (ADEs) were observed 
in DAA-group patients during HCV treatment. Two of 
the patients experienced fatigue and one experienced 
insomnia. Fifteen of the thirty-two patients of the P/
R-group experienced ADEs during HCV treatment. Ten 
experienced fatigue with nausea, three diarrhea and 
two cefalea.
DISCUSSION
In our study, psoriatic patients of the DAA-group had 
a better prognosis compared to the P/R-group, both in 
progression of psoriasis (and consequent worsening of 
quality of life) and in eradication of HCV. Patients with 
a worse prognosis treated with P/R could be attributed 
to two possible causes: (1) Interferon "itself" has 
dermatological side effects[15], worsening psoriasis and (2) 
DAAs are more effective than interferon-based therapy 
increasing the rates of SVR (even up to 100%)[16], 
suggesting that HCV could promote psoriatic disease.
Eradication treatment of HCV with interferon has 
been described as the drug that can induce de novo 
psoriasis or flares in psoriatic patients[17-19]. The flare 
usually occurs one to 6 wk after starting interferon-α and 
may lead to its discontinuation[20].
There appears to be an intricate relationship 
between psoriasis and HCV infection as seen in previous 
reports. HCV in predisposed individuals upregulates 
cathelecidin, Toll like receptor 9 (TLR-9) and interferon 
(IFN)-γ which are all involved in the development of 
psoriasis plaques. Pegylated interferon may also initiate 
and maintain psoriasis inflammation by activating Th1 
and Th17 via myeloid DCs[7,21]. Cathelecidin bonds self-
DNA. It is released after various injury stimuli via TLR-9 
plasmacytoid and DCs to produce type Ⅰ interferons 
(α/β), which drives T-cell polarization towards Th1 and 
Th17 via myeloid DCs. This initiates the trigger and 
further maintenance of psoriasis[7]. Likewise, pegylated 
interferon may act directly via myeloid resident DCs on 
Th1 cells and also on Th17 cells at the same time by 
increasing their activation and release of IL-17. IL-17 is 
a chemo-attractant for neutrophils to the skin and IL-22 
causes keratinocyte hyperproliferation[21]. Despite these 
preliminary hypotheses, data regarding the association 
of HCV and psoriasis remain unclear and a matter of 
Table 2  Levels of sIL-2R, ALT, and HBV DNA in the sera of patients with chronic hepatitis B virus infection (mean ± SD)
DAA-group P/R-group P  value
PASI (T0), mean ± SD 11.6 ± 5.2   9.4 ± 3.5 -
PASI (T1), mean ± SD   5.2 ± 1.6   8.3 ± 4.5 < 0.005
Biological treatment shifts, n (%) - 8 (25) < 0.001
Topical treatments (T0), n (%) 27 (100) 32 (100) -
Topical treatments (T1), n (%) 27 (100) 32 (100) -
DLQI (T0), mean ± SD    13 ± 2.3    12 ± 3.1 -
DLQI (T1), mean ± SD   4.2 ± 2.3    11 ± 2.3 < 0.001
HCV treatment details, n (%) Sofosbuvir + daclatasvir: 25 (92.6) Pegylated interferon-2α + ribavirin -
Sofosbuvir + simeprevir + ribavirin: 1 (3.7)  32 (100)
Sofosbuvir + ribavirin: 1 (3.7) 
Laboratory tests, mean ± SD
T0
  ALT   45.6 ± 16.5    43 ± 9.2 -
  AST   54.6 ± 5.51   52.4 ± 12.5 -
  GGT     42.0 ± 13.59   43.3 ± 14.6 -
T1
  ALT 42.21 ± 12.4    43 ± 8.5 -
  AST 51.3 ± 4.2 51.9 ± 8.9 -
  GGT   40.8 ± 12.2   42.9 ± 14.1 -
Dropout HCV-treatment, n (%) 0/27 (0)  9/32 (28.1) < 0.005
SVR, n (%) 27/27 (100) 12/32 (37.5) < 0.005
Categorical variables are expressed as n (%), and compared by χ 2 or Fisher’s exact test. Numeric variables are expressed as median and SD, and compared 
by Mann–Whitney or Kruskall–Wallis tests. Statistical significance was considered as a P-value of < 0.05. DAA: New Direct-Acting Antiviral Agent; P/R: 
Pegylated interferon-2α plus ribavirin; PASI: Psoriasis Area Severity Index; T0: Baseline time (before starting the hepatitis C eradication treatment); T1: Six 
months after the end of hepatitis C eradication treatment; DLQI: Dermatology Quality of Life Index; HCV: Hepatitis C virus; SVR: Sustained virological 
response; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase. 
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debate. Some studies show no association[22] while 
others show an increased prevalence of psoriasis among 
HCV-patients as reported by Cohen[8]. Furthermore, 
limited data is present in literature regarding psoriasis 
induction and exacerbation due to interferon in HCV-
psoriatic patients[21].
Experimental studies have shown that an intradermal 
injection of IFN-γ, both on the non-lesional psoriatic 
and healthy skin, causes an elevation of inflammatory 
products such as TNF, IL-23 and inducible nitric oxide 
synthase which are characteristic of psoriatic plaques[23]. 
An association between HCV infection and psoriasis has 
been suggested. The prevalence of HCV in psoriatic 
patients was increased compared to controls (1.03% vs 
0.56%; P < 0.001)[8]. In a single center cross-sectional 
study conducted in a Japanese university hospital, the 
frequency of HCV infection was significantly higher in 
psoriatic (7.5%) than in non psoriatic patients (3.3%) in 
overall ages[24]. Interestingly, when stratified by age at 
the first visit, HCV infection frequency was significantly 
higher in patients with psoriasis than in controls aged 
over 60 years (11.8% vs 6.6%, respectively, P = 
0.0215) and 70 s (19.5% vs 7.3%, P < 0.0001)[24]. 
Psoriatic patients with CHC were significantly older 
at onset than non psoriatic CHC patients (median, 
54 vs 39 years)[24]. There was also a stronger male 
predominance (male/female ratio, 4.4:1), similar family 
history of psoriasis, higher association of diabetes 
mellitus and hypertension, and significantly lower 
body mass index, in an age-stratified (≥ 40 years) 
analysis[24]. Psoriatic patients with CHC were less obese, 
but still had a higher frequency of diabetes mellitus 
and hypertension[24]. The authors hypothesized that 
psoriasis and HCV have pathophysiological factors 
in common with both mediated by proinflammatory 
cytokine tumor necrosis factor (TNF-α)[24]. In HCV 
infection, continuous inflammation mediated by TNF-α 
leads to liver cirrhosis and diabetes mellitus[24]. The link 
between psoriasis and HCV infection has been shown 
experimentally in a recent study of Chun et al[7]; the 
authors performed two 2 mm punch biopsies of lesional 
and nonlesional skin in 10 patients who were HCV-
negative psoriatic and 7 HCV-positive psoriatic patients. 
The biopsies were used to measure cathelicidin, TLR9 
and IFNc mRNA expression by quantitative reverse- 
transcriptase polymerase chain reaction (qRT-PCR)[7]. 
The mRNA expression was calculated relative to the 
housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and demonstrated that the 
cutaneous levels of inflammatory genes in HCV positive 
psoriatic patients are higher than the levels in patients 
with only psoriasis[7]. The increased cutaneous levels 
of cathelicidin, TLR9 and IFNc of HCV-positive psoriatic 
patients as compared to HCV-negative psoriatics 
suggest that HCV infection may predispose patients 
to developing psoriasis[7]. These findings seem to be 
confirmed clinically due to the worse prognosis of 
psoriasis in HCV-positive patients[7,25]. The mean PASI 
score is significantly higher in cohorts of patients affected 
with hepatitis C than those with psoriasis alone[7,25].
In line with previous studies, our study confirmed 
that bDMARDs are safe in psoriatic patients with HCV 
infection[26-29]. In literature bDMARDs are safe either 
in psoriatic patients with HCV infection and past HBV 
infection[30]. Patients in the DAA-group had a significantly 
better response to bDMARDs compared to P/R-group, 
requiring a smaller transition to different bDMARDs[10]. 
This may be due to a more favorable outcome in 
psoriasis (due to interferon-free therapy and greater HCV 
eradication), but also due to intrinsic DAAs action[31]; 
Immune reconstitution occurs in patients with whom 
HCV was successfully eradicated via DAAs therapy[31]. 
Restoration of the CD4+ T-cell compartment in the 
peripheral blood and a re-differentiation of the T 
lymphocyte memory compartment resulted in a more 
effector memory T cell population and a reduction in 
expression of the co-inhibitory molecule TIGIT in bulk 
T lymphocytes[31]. Burchill et al[31] observed a partial 
reversal of the exhausted phenotype in HCV-specific 
CD8+ T cells and a dampening of the activation state in 
peripheral NK cells. Spaan et al[32] showed that viral load 
decline, as a consequence of DAAs therapy in patients 
with chronic hepatitis C infection, reduces serum levels 
of NK cell-stimulating cytokines and causes correction 
of the altered NK cell phenotype observed in chronic 
HCV patients. CHC is characterised by innate immune 
activation with increased interferon-stimulated gene 
expression and by an altered phenotype of interferon-
responsive natural NK cells[33]. DAAs treatment could 
improve the pro-inflammatory status due both to 
psoriasis and to the HCV infection making bDMARDs 
actions more effective.
The current study contains some limitations that 
need to be taken into account. This is a retrospective 
observational study conducted in a single Italian centre, 
thus our conclusions should be interpreted with caution 
and cannot be generalized to all HCV-positive psoriatic 
patients. In particular, a general under-reporting of 
toxicity, as with all observational studies, is possible. 
Another limitation is the small sample size and the 
relatively short follow-up. This is the first study to 
compare DAAs to P/R for the management of HCV-
positive psoriatic patients and unmeasured confounding 
variables could influence our findings. Thus, larger 
series with long-term follow-up are required to confirm 
this preliminary data.
In conclusion, new DAAs are more effective than 
P/R in the eradication of HCV and the control of 
symptoms in psoriatic patients with CHC. Future studies 
are needed to evaluate the effects of DAAs in this 
clinical setting, which may further aid in elucidating the 
etiologic and pathogenetic mechanism of psoriasis.
ARTICLE HIGHLIGHTS
Research background
Up to 0.06% of people suffer from both psoriasis and hepatitis C virus (HCV). 
Psoriatic patients with HCV are excluded by randomized controlled clinical trials. 
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Research motivation
No data is currently available concerning the concomitant administration 
of biological drugs and the medications approved for the treatment of HCV 
infection, as new Direct-Acting Antiviral agents (DAAs).
Research objectives
Evaluate the outcomes in biological treatment and quality of life of psoriatic 
patients with chronic hepatitis C (CHC) treated with new DAAs compared to 
pegylated interferon-2α plus ribavirin (P/R) therapy.
Research methods
Psoriatic patients, in biological therapy, who underwent anti-HCV treatment 
were retrospectively reviewed. The patients were divided into two groups: 
patients that underwent therapy with DAAs and patients that underwent HCV 
treatment with P/R. Patients were assessed for Psoriasis Area Severity Index 
(PASI) scores and the Dermatology Quality of Life Index (DLQI) switching to a 
different bDMARD, dropout of HCV therapy and sustained virological response 
(SVR).
Research results
Twenty-seven patients were treated with DAAs and thirty-two with P/R. At three 
months, after completion of antiviral therapy, the DLQI and the PASI scores 
were significantly lower (P < 0.001 and P < 0.005, respectively) in DAAs group 
compared with P/R group. None of the patients in the DAAs group compared to 
the eight patients of the P/R group needed a change in biological treatment.
Research conclusions
DAAs seem to be more effective and safe than P/R in HCV-positive psoriatic 
patients on biological treatment.
Research perspectives
This is the first study which evaluated the HCV treatment of psoriatic patients 
on biological agents. Future studies are needed to evaluate the effects of DAAs 
in this clinical setting, which may further aid in elucidating the etiologic and 
pathogenetic mechanism of psoriasis.
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